Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer...
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
About this item
Full title
Author / Creator
Gandara, David R. , Paul, Sarah M. , Kowanetz, Marcin , Schleifman, Erica , Zou, Wei , Li, Yan , Rittmeyer, Achim , Fehrenbacher, Louis , Otto, Geoff , Malboeuf, Christine , Lieber, Daniel S. , Lipson, Doron , Silterra, Jacob , Amler, Lukas , Riehl, Todd , Cummings, Craig A. , Hegde, Priti S. , Sandler, Alan , Ballinger, Marcus , Fabrizio, David , Mok, Tony and Shames, David S.
Publisher
New York: Nature Publishing Group US
Journal title
Language
English
Formats
Publication information
Publisher
New York: Nature Publishing Group US
Subjects
More information
Scope and Contents
Contents
Although programmed death-ligand 1–programmed death 1 (PD-L1–PD-1) inhibitors are broadly efficacious, improved outcomes have been observed in patients with high PD-L1 expression or high tumor mutational burden (TMB). PD-L1 testing is required for checkpoint inhibitor monotherapy in front-line non-small-cell lung cancer (NSCLC). However, obtaining...
Alternative Titles
Full title
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
Authors, Artists and Contributors
Author / Creator
Paul, Sarah M.
Kowanetz, Marcin
Schleifman, Erica
Zou, Wei
Li, Yan
Rittmeyer, Achim
Fehrenbacher, Louis
Otto, Geoff
Malboeuf, Christine
Lieber, Daniel S.
Lipson, Doron
Silterra, Jacob
Amler, Lukas
Riehl, Todd
Cummings, Craig A.
Hegde, Priti S.
Sandler, Alan
Ballinger, Marcus
Fabrizio, David
Mok, Tony
Shames, David S.
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2084917533
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2084917533
Other Identifiers
ISSN
1078-8956
E-ISSN
1546-170X
DOI
10.1038/s41591-018-0134-3
